Compendia Transparency

Through the process established by the Centers for Medicare and Medicaid Services (CMS), IBM® Micromedex® DRUGDEX® is recognized by CMS as a compendium for the determination of payment for medically-accepted off-label uses for anti-cancer regimens. Effective January 1, 2010, new requirements were implemented that include a provision for providing transparency of processes used to evaluate therapies and to identify potential conflicts of interest. Specifically, publishers of compendia must now make the following information available via their public websites:\(^1\):

1. Provide criteria used to evaluate the request (therapy)
2. Disclose evidence considered
3. Provide names of individuals who have substantively participated in the development of the compendia recommendations and disclose any potential conflicts of interest
4. Provide meeting minutes and records of votes for disposition of the request (therapy)

To meet these requirements, documents detailing this information for each drug/off-label use pair published on or after January 1, 2010 are posted at the Micromedex website on www.ibm.com. Information is organized by drug name, with the document title indicating the off-label use. Further transparency regarding Micromedex Off-Label processes can be found in the *Micromedex Off-Label Uses Policy* document.
© Copyright IBM Corporation 2019
IBM Corporation
New Orchard Road,
Armonk, NY 10504
Produced in the United States
of America
July 2019
IBM, the IBM logo and ibm.com
and IBM Watson Health are trademarks
of IBM Corporation in the United States,
other countries or both. Truven Health
Analytics and its respective logo are
trademarks of Truven Health Analytics
in the United States, other countries
or both. All other company or product
names are registered trademarks
or trademarks of their respective
companies. A current list of IBM
trademarks is available on the Web at
“Copyright and trademark information”

This document is current as of the initial
date of publication and may be changed
by IBM at any time. Not all offerings are
available in every country in which
IBM operates.

The information in this document is
provided “as is” without any warranty,
express or implied, including without
any warranties of merchantability,
fitness for a particular purpose
and any warranty or condition of
non-infringement. IBM products are
warranted according to the terms and
conditions of the agreements under
which they are provided.

The client is responsible for ensuring
compliance with all applicable laws
and regulations applicable to it.

IBM does not provide legal advice or
represent or warrant that its services
or products will ensure that the client is
in compliance with any law or regulation.

The performance data and client
examples cited are presented for
illustrative purposes only. Actual
performance results may vary
depending on the specific configurations
and operating conditions. It is the user’s
responsibility to evaluate and verify the
operation of any other products or
programs with IBM product
and programs.

Statement of Good Security Practices:
IT system security involves protecting
systems and information through
prevention, detection and response
to improper access from within and
outside your enterprise. Improper
access can result in information being
altered, destroyed, misappropriated or
misused or can result in damage to
or misuse of your systems, including for
use in attacks on others. No IT system
or product should be considered
completely secure and no single
product, service or security measure
can be completely effective in
preventing improper use or access.
IBM systems, products and services
are designed to be part of a lawful,
comprehensive security approach,
which will necessarily involve additional
operational procedures, and may
require other systems, products or
services to be most effective. IBM does
not warrant that any systems, product
or services are immune from, or will
make your enterprise immune from, the
malicious or illegal conduct of any party.

About IBM Watson Health
Each day, professionals throughout the health
ecosystem make powerful progress toward a healthier
future. At IBM Watson Health, we help them remove
obstacles, optimize efforts and reveal new insights
to support the people they serve. Working across the
landscape, from payers and providers to governments
and life sciences, we bring together deep health
expertise; proven innovation; and the power of
artificial intelligence to enable our customers to
uncover, connect and act — as they work to solve
health challenges for people everywhere.

For more information on IBM Watson Health,
visit: ibm.com/watsonhealth

www.govinfo.gov/content/pkg/FR-2009-11-25/pdf/E9-
26502.pdf (accessed March 8, 2010).

Micromedex® and DRUGDEX® are registered
trademarks of IBM.